

2020 Annual Breast Carcinoma Result Comparison Report

Tests Performed by Summit Pathology

The following tables summarize results from tests performed and read by Summit Pathology for all clients. All tests were performed and interpreted by Summit Pathology unless noted otherwise in the summary tables.

Estrogen and Progesterone Receptor Testing

Estrogen Receptor IHC Results						
	All Results		Premenopausal		Postmenopausal	
	n	Percentage ¹	n	Percentage	n	Percentage ²
Negative	187	19.26%	52	20.80%	135	18.72%
Positive	784	80.74%	198	79.20%	586	81.28%

¹ Estrogen receptor negative benchmark is at or below 30%

² Women 55 and older were classified as postmenopausal.

Progesterone Receptor IHC Results						
	All Results		Premenopausal		Postmenopausal	
	n	Percentage ¹	n	Percentage	n	Percentage ²
Negative	318	33.09%	81	32.53%	237	33.29%
Positive	643	66.91%	168	67.47%	475	66.71%

¹ Progesterone receptor negative benchmark is 10-15% greater than estrogen receptor negative results. Progesterone receptor negative test results exceeded estrogen receptor negative test results by 14.44% in 2019.

² Women 55 and older were classified as postmenopausal.

Estrogen and Progesterone Receptor Negative Results: Frequency of Well-differentiated Carcinomas and Specific Tumors

Classification ¹	Results	Estrogen Receptor Negative		Progesterone Receptor Negative	
		n	Percentage	n	Percentage
Well-differentiated	326	4	1.23%	31	9.51%

¹ See medical director's comments below.

HER2/neu Testing

	All Grades		Low Grade		Intermediate Grade		High Grade	
	n	Percentage ¹	n	Percentage	n	Percentage	n	Percentage
Equivocal	2	0.36%	1	0.55%	1	0.43%	—	—
Negative	475	84.37%	175	96.69%	193	82.83%	107	71.81%
Positive	86	15.28%	5	2.76%	39	16.74%	42	28.19%

¹ Benchmark for overall HER2/neu results is 10-25% positive.

Summary statistics represent combined IHC and amplification study results.

Comments by Medical Director

Medical Director : _____

Date: _____

Prepared by Corey Handelsman on 03/12/2021